B
Bullisch
Bullisch · 25%AKYA
$1.21
Szenariopreis
$1.290
-0.066 (-5.15%)Zum Schluss
Loading chart…
- Hoch
- 1.640
- Eröffnung
- 1.410
- Volumengewichteter Durchschnittskurs
- 1.41
- Volumen
- 715.25K
- Marktkap.
- 120.50M
- Tief
- 1.290
- Umsatz
- 1.01M
- EV/EBITDA, TTM
- -7.63
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Akoya Biosciences Inc (AKYA) beträgt -2.50, verglichen mit dem 5-Jahres-Durchschnitt von -5.35.
Alphio-AI-Kursszenarien für AKYA
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.505-23NewsfilterKent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
9.005-23PRnewswireNew Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
8.505-21SeekingAlphaAkoya surges as unsolicited buyout offer risks Quanterix merger
7.004-28Globenewswire$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AKYA, WTMA, PLYA, QTRX to Act Now
7.004-24GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PPBI, SSBK, AKYA on Behalf of Shareholders
AKYA FAQ – beantwortet von Alphio AI
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.